Fundraising FoxSanofi Ventures — 2020 Investments
4 investments dated 2020 · listed companies and verified rows first · show all
Abcuro develops therapies that target highly cytotoxic T cells for autoimmune diseases, including its lead candidate ulviprubart for inclusion body myositis.
BiotechHealthtechNewton, US
Steven A. Greenberg(Chief Scientific Advisor & Co-Founder)Steven A. Greenberg, MD(Chief Scientific Advisor & Co-Founder)John Alexander Martin(Executive Officer, Director)Stefano Gulla(Founder)Evan Thompson(Executive Officer)David de Graaf(Executive Officer, Director)
Board seatJason P. Hafler· per SEC Form D
Co-investorsBain Capital Life SciencesNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalMass General Brigham VenturesREDMILE+9 more
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)
BoardAndrew Schwab(Director)in
Board seatJason P. Hafler· per SEC Form D
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)The Column GroupAbingworth+2 more
A biopharmaceutical company developing a pipeline of long-acting therapeutic candidates, including GLP-1 receptor agonists, amylin DACRAs, a PYY receptor agonist, and a glucagon receptor agonist.
BiotechSaratoga, US
Mitragotri Mitragotri(Executive Officer, Director)Ravi Srinivasan(Executive Officer, Director)in
Co-investors7G BioVenturesCerity Partners VenturesColorcon VenturesHikma VenturesJDRF T1D Fund
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in
Co-investorsMRL Ventures FundYsios CapitalGilde HealthcareNovo HoldingsREDMILE
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.